• Publications
  • Influence
A Novel 111In-Labeled Anti–Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer
TLDR
An 111In-radiolabeled anti-PSMA Nanobody is developed, showing good tumor targeting, low uptake in nontarget tissues, and low renal retention, allowing excellent SPECT/CT imaging of PCa within a few hours after injection. Expand
Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent
TLDR
The preclinical application of PSMA I&T, a DOTAGA-chelated urea-based PSMA inhibitor, for SPECT/CT imaging and radionuclide therapy of prostate cancer is presented and indicates that PSMA-specific uptake in kidneys can be successfully tackled using blocking agents such as 2-PMPA. Expand
Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists.
TLDR
24 derivatives based on a compound scaffold patented by Chemocentryx and obtained CXCR7 ligands with pK(i) values ranging from 5.3 to 8.1 were synthesized and two key compounds were found to be high-potency ligands that induce recruitment of β-arrestin2 and subsequent internalization of CX CR7, making them important tool compounds in future CxCR7 research. Expand
Radiopeptides for Imaging and Therapy: A Radiant Future
TLDR
This short review highlights novel strategies to improve the application of radiopeptides for imaging and therapy. Expand
213Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts.
TLDR
213Bi-PSMA I&T and 213Bi-JVZ-008 showed efficient and rapid tumor targeting and produced DSBs in PSMA-expressing LNCaP cells and xenografts in PCa therapy. Expand
Preclinical Comparison of Al18F- and 68Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonists for PET Imaging of Prostate Cancer
TLDR
GRPR specificity was confirmed by significantly reduced tumor uptake of the 3 tracers after coinjection of a 100-fold excess of unlabeled JMV4168 or JMV5132, and tracer biodistribution was determined by ex vivo measurements. Expand
In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies
TLDR
This data shows that co-injection of the enzyme inhibitor PA greatly enhances the theranostic potential of GRPR-radioantagonists for future application in PCa patients. Expand
Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments
Neuroblastoma is the most common extracranial solid malignancy in children. At diagnosis, approximately 50% of patients present with metastatic disease. These patients are at high risk for refractoryExpand
...
1
2
...